{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:07:44Z","timestamp":1768000064744,"version":"3.49.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Globally, invasive fungal diseases (IFDs) have a significant impact in human health. With an increasing pediatric population at risk of IFD, effective antifungal drugs access and affordability should be ensured universally. The aim of our study was to characterize the global antifungal drug use in neonates and children and its variability between countries in different income groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data were extracted from the Global Antimicrobial Resistance, Prescribing and Efficacy in Neonates and Children Point Prevalence Survey project, consisting in 1 pilot and four 1-day Point Prevalence Survey between 2015 and 2017. The data had been entered through a study-specific web-based data collection tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>From a total of 13,410 children included, 7.8% (1048\/13,410) received at least 1 systemic antifungal drug: 9.5% (95% confidence interval: 8.9%\u201310.1%) in high income countries (HIC) versus 5.0% (95% confidence interval: 4.4%\u20135.6%) in low-middle income countries (LMIC) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). A significant proportion of patients on antifungals belonged to high-risk group for IFD (67.4%; 706\/1048); most of these were managed in HIC (72.8%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). The likelihood of receiving antifungals being in high-risk group was higher in HIC compared with LMIC (ratio of 5.8 vs. 3.4, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Antifungal prophylaxis was more likely prescribed in HIC (67.2% vs. 30.4%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Fluconazole was the most frequently prescribed drug. The proportional use of fluconazole was higher in LMIC compared with HIC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A significant variability of antifungal prescribing patterns was observed. The proportional use of systemic antifungals was twice as high in HIC compared with LMIC. More detailed data on access and antifungal use in limited-resource settings should be explored.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002983","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T18:05:22Z","timestamp":1615572322000},"page":"327-332","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Global Divergence of Antifungal Prescribing Patterns"],"prefix":"10.1097","volume":"40","author":[{"given":"Laura","family":"Ferreras-Antolin","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"MRC Centre for Medical Mycology, University of Exeter, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bielicki","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"Paediatric Pharmacology Group, University of Basel Children\u2019s Hospital, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, University of Exeter, United Kingdom"},{"name":"Paediatric Infectious Diseases, Great Ormond Street Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Infection and Immunity, St George\u2019s University of London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingfen","family":"Hsia","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, University of Exeter, United Kingdom"},{"name":"School of Pharmacy, Queens\u2019 University Belfast, Belfast, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision.","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2015.10.004","article-title":"The global burden of fungal diseases.","volume":"30","author":"Vallabhaneni","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children.","volume":"6","author":"Pana","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/INF.0000000000000101","article-title":"Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: a single center 30-year experience.","volume":"33","author":"Castagnola","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1473-3099(17)30319-5","article-title":"Recovery from serious fungal infections should be realisable for everyone.","volume":"17","author":"Tudela","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/jac\/dkw325","article-title":"Global access to antifungal therapy and its variable cost.","volume":"71","author":"Kneale","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2214-109X(19)30071-3","article-title":"Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries.","volume":"7","author":"Hsia","year":"2019","journal-title":"Lancet Glob Health"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) study.","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1017\/ice.2017.40","article-title":"Variability in antifungal and antiviral use in hospitalized children.","volume":"38","author":"Goldman","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/INF.0000000000002463","article-title":"Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the Pediatric Antifungal Stewardship: optimizing antifungal prescription study.","volume":"38","author":"Ferreras-Antol\u00edn","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MOP.0b013e32835c1cbe","article-title":"Global challenges in pediatric oncology.","volume":"25","author":"Rodriguez-Galindo","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pbc.25810","article-title":"Improving care for children with cancer in low- and middle-income countries\u2013a SIOP PODC initiative.","volume":"63","author":"Arora","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet Oncology Commission.","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3201\/eid2302.152042","article-title":"Candidiasis IDSA guidelines 2016.","volume":"23","author":"Denning","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"suppl 7","key":"R23-20250615","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jphp.12780","article-title":"Echinocandins in antifungal pharmacotherapy.","volume":"69","author":"Patil","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/mmy\/myy084","article-title":"The use of echinocandins in hospitalized children in the United States.","volume":"57","author":"Downes","year":"2019","journal-title":"Med Mycol"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","article-title":"Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global Point Prevalence Survey.","volume":"6","author":"Versporten","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based Point Prevalence Survey in 73 hospitals worldwide.","volume":"32","author":"Versporten","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dkv418","article-title":"The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) Point Prevalence Survey: developing hospital-quality indicators of antibiotic prescribing for children.","volume":"71","author":"Versporten","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:03:25Z","timestamp":1750003405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002983"}},"subtitle":["Data From the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children Surveys"],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002983","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}